直腸がんの治療を受けている患者の周術期転帰に対する術前の運動と栄養の最適化の影響: PROPEL 試験
The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.
The names of the groups in this research study are:
- Group A: Prehabilitation program
- Group B: Usual Care
調査の概要
詳細な説明
This is a non-blinded, randomized control trial to determine the feasibility of a hybrid-model, prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant therapy (chemotherapy and/or radiation) before surgical resection. Investigators hope that prehabilitation will result in improved outcomes after surgery.
Participants will be randomized into one of the study groups: Group A: prehabilitation program, or Group B: usual care. Randomization means that a participant is placed into a group by chance.
The research study procedures include screening for eligibility, in-clinic visits, physical exams, exercise training, blood tests, and questionnaires.
It is expected that about 40 participants will take part in this research study.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jeffrey Meyerhardt, MD, MPH
- 電話番号:617-632-6855
- メール:jeffrey_meyerhardt@dfci.harvard.edu
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Brigham and Women's Hospital
-
コンタクト:
- Joel Goldberg, MD
- 電話番号:617-732-8460
- メール:JGOLDBERG1@PARTNERS.ORG
-
主任研究者:
- Joel Goldberg, MD
-
Boston、Massachusetts、アメリカ、02115
- 募集
- Dana-Farber Cancer Institute
-
主任研究者:
- Jeffrey Meyerhardt, MD
-
コンタクト:
- Jeffrey Meyerhardt, MD, MPH
- 電話番号:617-632-6855
- メール:jeffrey_meyerhardt@dfci.harvard.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age greater than or equal to 18 years at time of enrollment.
- English-Speaking.
- Diagnosis of clinical stage II-III rectal cancer.
- Planned, ongoing or just completed neoadjuvant treatment, including either 1) chemoradiation, 2) total neoadjuvant therapy (TNT), or 3) chemotherapy only; and anticipated surgical resection to follow.
- Able to understand the study procedures, agree to participate in the study program, and voluntarily provide informed consent.
Exclusion Criteria:
- Distant metastatic disease known at the time of diagnosis.
- Functional incapacity (i.e., incapable of performing exercise testing).
- Comorbid conditions or cognitive/physical impairments that contraindicate exercise.
- Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer.
- Currently enrolled in a separate clinical trial that would prohibit them from performing the tasks instructed in this trial.
- Currently participating in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described intervention, where additional exercise done regularly will contaminate the intervention effects.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Group A: Prehabilitation Program
Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:
|
A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed. |
|
介入なし:Group B: Usual Care
Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Enrollment Rate
時間枠:Baseline
|
The proportion of eligible individuals that are enrolled to the study. Feasibility of the intervention is defined as an enrollment rate of greater than 10% of approached, eligible participants. |
Baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adherence Rate to the Prehabilitation Program
時間枠:At post-intervention (approximately Week 4)
|
The number of intervention assessments completed by participants in Group A. Feasibility of the intervention is defined as at least 50% of participants adhering to at least 50% of the prescribed assessments of the prehabilitation program. |
At post-intervention (approximately Week 4)
|
|
Completion Rate of Physical Function Testing (Group A)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants. |
At post-intervention (approximately Week 4)
|
|
Completion Rate of Physical Function Testing (Group B)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants. |
At post-intervention (approximately Week 4)
|
|
Completion Rate of Questionnaire Assessments
時間枠:At baseline and the postoperative visit (approximately Week 9)
|
Defined as the number of questionnaires completed by all participants. |
At baseline and the postoperative visit (approximately Week 9)
|
|
Participant Fall Rate (Group A)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of falls attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Participant Fall Rate (Group B)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of falls attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Hospitalization (Group A)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Hospitalization (Group B)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Musculoskeletal Injury (Group A)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Musculoskeletal Injury (Group B)
時間枠:At post-intervention (approximately Week 4)
|
Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Change in Resting Blood Pressure from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Assessed by resting blood pressure. The average systolic blood pressure (of two measurements from each arm) will be recorded. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Cardiorespiratory Fitness from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Assessed by VO2peak by a graded maximal (or submaximal if equipment is unavailable) cycle exercise stress test. VO2peak is defined as the highest values of oxygen uptake averaged among every 30-second interval during the test. VO2peak will be reported in both relative (ml·kg-1·min-1) and absolute (L/min) terms. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Short Physical Performance Battery (SPPB) Score from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Assessed by the Short Physical Performance Battery (SPPB) which is comprised of three sections: 1) balance with feet together, semi tandem, and full tandem is held for up to 10 seconds with no support and measure in seconds. Scores are summed for the measure of balance for a range of 0 to 30 seconds; 2) usual gait speed over four meters is timed (seconds); and 3) chair stand where the time(s) to complete five chair sit-to-stands is recorded. Each of the three performance measures is assigned a score ranging from 0 to 4, with 4 indicating highest level of performance and 0 indicating inability to complete test. A summary score ranging from 0 (worst performers) to 12 (best performers) is calculated by adding walking speed, chair stands and balance scores. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Muscle Strength from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
The 1RM (repetition maximum) will be estimated from 10RM muscle strength tests on two exercises: 1) leg press, 2) chest press. 1RM values will be calculated and reported using validated equations. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Height from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Height will be measured using a stadiometer, rounding up to the nearest 0.1 cm |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Weight from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Assessed by weight, rounding up to the nearest 0.1 kg. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Waist Circumference from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Waist circumference will be measured, rounding up to the nearest 0.1cm. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Hip Circumference from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Hip circumference will be measured, rounding up to the nearest 0.1cm. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Body Mass Index from Baseline to Post-Intervention
時間枠:From baseline to post-operative visit (approximately week 9)
|
Body composition will be assessed via bioelectrical impedance using a validated device. The device will estimate body fat using an algorithm based on participant age, sex, height, and body weight. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Nutritional Status from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Nutritional Status from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Quality of Life from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the European Organization for Research and Treatment of Cancer's (EORTC's) Quality of Life (QOL) core questionnaire (QLQ C-30), a validated, 30-item instrument designed to quantify and measure QOL in cancer participants. Questions are rated on a four point scale from 1 "Not at all" to 4 "Very much. All items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Quality of Life from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Pittsburgh Sleep Quality Index (PSQI) Score from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in PSQI Score from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group A)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill). |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group B)
時間枠:From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill). |
From baseline to postoperative visit, up to 9 weeks
|
|
Length of Hospitalization Post-Surgery (Group A)
時間枠:30 Days
|
Defined as the number of days of hospitalization post-surgery. |
30 Days
|
|
Length of Hospitalization Post-Surgery (Group B)
時間枠:30 Days
|
Defined as the number of days of hospitalization post-surgery. |
30 Days
|
|
Time To Return of Bowel Function Post-Surgery (Group A)
時間枠:30 Days
|
Defined as the number of days to a return of bowl function post-surgery. |
30 Days
|
|
Time To Return of Bowel Function Post-Surgery (Group B)
時間枠:30 Days
|
Defined as the number of days to a return of bowl function post-surgery. |
30 Days
|
|
Discharge Disposition (Group B)
時間枠:30 Days
|
Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics. |
30 Days
|
|
Discharge Disposition (Group A)
時間枠:30 Days
|
Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics. |
30 Days
|
協力者と研究者
捜査官
- 主任研究者:Jeffrey Meyerhardt, MD, MPH、Dana-Farber Cancer Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 24-384
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 共有時間枠
Data can be shared no earlier than 1 year following the date of publication
IPD 共有アクセス基準
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。